We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Concepta Plc | LSE:CPT | London | Ordinary Share | GB00BYZ2R301 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.98 | 1.90 | 2.20 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMCPT
RNS Number : 0804C
Concepta PLC
27 September 2018
27 September 2018
Concepta plc
("Concepta" or the "Company")
Interim Results
This announcement contains inside information which is disclosed in accordance with the Market Abuse Regulation which came into effect on 3 July 2016.
Concepta plc (AIM: CPT), the innovative UK healthcare company and developer of the proprietary home test platform ("myLotus") and suite of emerging test products targeting the personalised mobile health market with a primary focus on women's fertility announces its interim results for the six months to 30 June 2018.
Operational Highlights
-- Preparing for UK launch and scale-up of myLotus -- Completion of CE-Mark submission - Awaiting CE-Mark certification
-- Successful completion of clinical studies in UK and China further bolstering product confidence
Financial Position
-- Completion of oversubscribed GBP2m placing @ 4p per share (post 30 June) -- Cash balance at the period end was GBP248,172 (H1 2017 GBP1,234,974) -- Loss for the period of GBP1,490,349 (H1 2017 GBP1,083,905) -- Cash outlay for Doncaster factory facilities and equipment GBP441,039 (H1 2017 GBP512,686)
Chairman's Statement
Following my appointment in July 2018, I have spent the past few months carefully reviewing the business and strategy and I am pleased to report the half year results for the six months to 30 June 2018. My report provides an update on the significant progress being made to strengthen the operational robustness of the business in advance of launching our first home test (self test) fertility product to the UK market.
As part of our UK product launch preparations we have recently completed our milestone clinical user testing studies and stability trials in support of our regulatory CE-mark submission. The CE-Mark Notified Body (BSI) have also completed their in-depth audit of our product. Pending receipt of the final certification we anticipate launching the myLotus product to the UK market over the coming months.
The UK product launch marks an important and exciting milestone in the Company's development. The Company has worked diligently towards this revenue generating goal and is now poised to deliver its first innovative product to an attractive UK fertility market.
The myLotus UK user trial was carried out at the Clarence Medical Centre in North Wales and independently tested our product proposition for fertility monitoring and menstrual cycle hormone assessment. The ability for women to home monitor (self test) their hormone profile over their cycle provides a level of fertility information which is unavailable today. It also provides women trying for a baby or specifically those with fertility issues a personal insight to help identify their optimal time to conceive and/or provide their doctors with information that may help better manage their fertility journey and early stage pregnancy.
Added to the successful North Wales user study we have also recently completed successful product assessment studies in Bedford, UK and Shanghai, China. Both these studies provided independent product assessment and benchmark validation against traditional laboratory-based tests.
Progress in China has been disappointing and as a result we will be re-balancing our resource commitment to China. We will focus our prime attention on our UK home market and the subsequent roll-out of myLotus across Europe. Whilst the positive study results from the Changhai hospital, Shanghai have helped bolster our confidence in the China product, given our limited bandwidth and revenue growth objectives our efforts will be aligned to support the successful launch of myLotus in the UK.
Our UK sales and marketing channels are being developed across business-to-business (B2B) and business-to-consumer (B2C) channels. Our B2B channels include discussions with both large retail healthcare consumer groups as well as smaller fertility test providers and key opinion leaders. Our B2C offering is adopting a digital online marketing strategy with customers engaged via social media, content, email and search engine marketing enabling customers to acquire myLotus through our eCommerce platform.
Our Doncaster manufacturing facility has now completed the installation and validation of its automated production line for the manufacture of our ovulation and pregnancy tests. The previous small-scale test manufacturing capacity at our Colworth laboratories has also been successfully transferred to Doncaster. Scale up and production of our test monitor continues to strengthen and we anticipate improved margins and further efficiencies in cost improvement commensurate with our sales volume growth.
Whilst recognising the myLotus monitor lends itself to the development of other fertility tests and health diagnostics, our efforts remain resolutely focused on realising the potential of our initial launch tests. Nevertheless, we remain open to collaborative research proposals and are in discussions with a number of groups to expand and accelerate our test and technology developments.
Following the recently announced Board changes with myself taking an active Executive Chairman role and Peter Dines providing his considerable industry expertise as Non Executive Director and representing our main investor (Mercia Technologies PLC), Erik Henau will step down from the Board as Chief Executive Officer with immediate effect and take up the role of Business Development Director to lead our new client sales drive. I am pleased to announce that David Darrock Chief Operating Officer, who has been instrumental to the delivery of the myLotus product, will be promoted to the Board with immediate effect. These changes reflect the Company entering a new stage of development as we transition from a laboratory-based research facility to a manufacturing and selling commercial company.
Financial review
-- The Group's total comprehensive loss for the six months to 30 June 2018 was GBP1,490,350 (H1 2017 GBP1,083,905)
-- Following the period end, the Company completed an oversubscribed GBP2m placing at 4p per share to bolster the Company's cash position.
-- The basic and diluted loss per share was 1.1 pence (six months to 30 June 2017 loss 1.0 pence).
-- Cash balance as at 30 June 2018 was GBP248,172 (30 June 2017 GBP1,234,974).
During the reporting period we have maintained a tight cost control across all areas of spending whilst ensuring the essential requirements of moving the company towards UK launch were not compromised.
Outlook
The Company continues to strengthen from an early stage start up and is positioning itself to take advantage of the imminent UK product launch of myLotus. The Company's short-term outlook remains firmly focused on revenue growth and a determination to deliver improved investor returns. We anticipate the following deliverables over the next reporting period;
-- UK product launch and revenues
-- The emergence of a highly motivated 'fertility' target group with a clear need for our products
-- Raised product profile and PR based on fertility demand for myLotus -- Marketing and planning to expand the myLotus product into new markets and test opportunities
I would like to thank our investors for their support, patience and understanding. The Board recognise there have been delays in delivering our products to market but with the changes made to the organisation and our pending UK launch we have the opportunity and expertise to deliver a globally leading product to a rapidly growing home testing diagnostic space. We are committed to delivering this for our investors.
Matthew Walls
Chairman
**S**
Enquiries:
The Company
Matthew Walls, Chairman
Tel: +44 (0) 1234 866601
SPARK Advisory Partners Limited (Nomad)
Neil Baldwin / Mark Brady
Tel: +44 (0)20 368 3550
Novum Securities
Colin Rowbury
+44 (0) 20 7399 9400
Yellow Jersey PR Limited (Financial PR)
Georgia Colkin / Joe Burgess/Katie Bairsto
Tel: +44 (0) 776 932 5254
About Concepta Plc:
Concepta PLC is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus, targeted at the personalised mobile health market with a primary focus on fertility and unexplained infertility in women.
myLotus is currently the only consumer product which allows both quantitative and qualitative home (self test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin (hCG) hormone level during pregnancy, facilitating higher conception rates and early diagnosis of fertility issues. The proposition of myLotus is to help women conceive naturally by identifying their window of fertility and optimal time for conception.
The Company anticipates receiving CE-mark certification for myLotus over the coming months and is preparing its B2C launch in the UK and Europe. The Company has identified a significant global market opportunity with revenue potential of the EU and Chinese unexplained infertility market estimated to be worth c.GBP600m per annum.
Concepta has also made progress in establishing relationships with a number of distributors in China where myLotus has been given cFDA approval. Concepta is initially targeting the traditional route to market in China through Chinese hospitals and plans to add the B2C route in the near future.
Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.
Consolidated statement of comprehensive income
For the 6 months ended 30 June 2018
Hot Features
Premium
Audited
Unaudited Unaudited 12 months
6 months to 6 months to to
31 December
30 June 2018 30 June 2017 2017
Notes GBP GBP GBP
------------------------- ------ ------------- -------------- ------------
Revenue 3 - - 108,115
Cost of sales 4 (307,623) (172,996) (519,522)
Gross loss (307,623) (172,996) (411,407)
Other administrative
expenses (1,175,736) (959,547) (1,925,482)
Share-based payments (19,428) (19,173) (109,523)
------------------------- ------ ------------- -------------- ------------
Administrative expenses (1,195,164) (978,720) (2,035,005)
------------------------- ------ ------------- -------------- ------------
Operating loss (1,502,787) (1,151,716) (2,446,412)
Finance income - 3 -
Finance expenses (11,210) - (3,355)
------------------------- ------ ------------- -------------- ------------
Loss before income
tax (1,513,997) (1,151,713) (2,449,767)
Tax credit 6 23,648 67,808 104,818
Loss for the period (1,490,349) (1,083,905) (2,344,949)
------------------------- ------ ------------- -------------- ------------
Attributable to owners
of the parent: (1,490,349) (1,083,905) (2,344,949)
Loss per ordinary
share - basic and
diluted (pence) 5 (1.1) (1.0) (2.1)
Consolidated statement of financial position
As at 30 June 2018
Unaudited Audited
30 June Unaudited 31 December
2018 30 June 2017 2017
Notes GBP GBP GBP
------------- ------ ------------ ----------------------------------------------------------------------------------------------- ------------
Non-current
assets
Property,
plant and
equipment 7 801,761 646,983 473,247
Intangible
assets 8 423,848 305,797 390,743
Total
non-current
assets 1,225,609 952,780 863,990
------------- ------ ------------ ----------------------------------------------------------------------------------------------- ------------
Current
assets
Inventories 356,529 200,226 296,548
Trade and
other
receivables 269,073 172,116 678,236
Corporation
tax
receivable 128,466 67,808 104,818
Cash and
cash
equivalents 248,172 1,234,974 1,537,759
------------- ------ ------------ ----------------------------------------------------------------------------------------------- ------------
Total
current
assets 1,002,240 1,675,124 2,617,361
------------- ------ ------------ ----------------------------------------------------------------------------------------------- ------------
Total assets 2,227,849 2,627,904 3,481,351
------------- ------ ------------ ----------------------------------------------------------------------------------------------- ------------
Current
liabilities
Trade and
other
payables 437,048 381,366 462,895
Loans and
borrowings 69,818 - 16,211
Total
current
liabilities 506,866 381,366 479,106
------------- ------ ------------ ----------------------------------------------------------------------------------------------- ------------
Non-Current
liabilities
Loans and
borrowings 251,969 - 62,310
------------- ------ ------------ ----------------------------------------------------------------------------------------------- ------------
Total
current
liabilities 251,969 - 62,310
------------- ------ ------------ ----------------------------------------------------------------------------------------------- ------------
Total
liabilities 758,835 381,366 541,416
------------- ------ ------------ ----------------------------------------------------------------------------------------------- ------------
Net assets 1,469,014 2,246,538 2,939,935
------------- ------ ------------ ----------------------------------------------------------------------------------------------- ------------
Share
capital 3,454,917 2,740,631 3,454,917
Share
premium
account 9,813,131 8,663,326 9,813,131
Capital
redemption
reserve 1,814,674 1,814,674 1,814,674
Retained
earnings (8,239,831) (5,488,438) (6,749,482)
Reverse
acquisition
reserve (6,044,192) (6,044,192) (6,044,192)
Share-based
payment
reserve 670,315 560,537 650,887
Total equity 1,469,014 2,246,538 2,939,935
------------- ------ ------------ ----------------------------------------------------------------------------------------------- ------------
The accompanying notes are an integral part of these financial statements.
Consolidated statement of changes in equity
For the 6 months ended 30 June 2018
Capital Reverse Share-based
Share Share redemption Retained acquisition payment
capital Premium reserve earnings reserve reserve Total
GBP GBP GBP GBP GBP GBP GBP
--------------- ------------- ------------- ------------ ------------- ------------- ------------- ------------
Equity as at
1 January
2017 2,740,631 8,663,326 1,814,674 (4,404,533) (6,044,192) 541,364 3,311,270
Loss for the
year - - - (2,344,949) - - (2,344,949)
--------------- ------------- ------------- ------------ ------------- ------------- ------------- ------------
Total
comprehensive
loss - - - (2,344,949) - - (2,344,949)
Issue of
shares net of
expenses 714,286 1,149,805 - - - - 1,864,091
Share-based
payments - - - - - 109,523 109,523
--------------- ------------- ------------- ------------ ------------- ------------- ------------- ------------
Equity as at
31 December
2017 3,454,917 9,813,131 1,814,674 (6,749,482) (6,044,192) 650,887 2,939,935
--------------- ------------- ------------- ------------ ------------- ------------- ------------- ------------
Loss for the
period - - - (1,490,349) - - (1,490,349)
--------------- ------------- ------------- ------------ ------------- ------------- ------------- ------------
Total
comprehensive
loss - - - (1,490,349) - - (1,490,349)
Share-based
payments - - - - - 19,428 19,428
--------------- ------------- ------------- ------------ ------------- ------------- ------------- ------------
Equity as at
30 June 2018 3,454,917 9,813,131 1,814,674 (8,239,831) (6,044,192) 670,315 1,469,014
--------------- ------------- ------------- ------------ ------------- ------------- ------------- ------------
Capital Reverse Share-based
Share Share redemption Retained acquisition payment
capital Premium reserve earnings reserve reserve Total
GBP GBP GBP GBP GBP GBP GBP
--------------- ---------- ---------- -------------- --------------- -------------- -------------- ------------
Equity as at
1 January
2017 2,740,631 8,663,326 1,814,674 (4,404,533) (6,044,192) 541,364 3,311,270
Loss for the
period - - - (1,083,905) - - (1,083,905)
--------------- ---------- ---------- -------------- --------------- -------------- -------------- ------------
Total
comprehensive
loss - - - (1,083,905) - - (1,083,905)
Share-based
payments - - - - - 19,173 19,173
--------------- ---------- ---------- -------------- --------------- -------------- -------------- ------------
Equity as at
30 June 2017 2,740,631 8,663,326 1,814,674 (5,488,438) (6,044,192) 560,537 2,246,538
--------------- ---------- ---------- -------------- --------------- -------------- -------------- ------------
The accompanying notes are an integral part of these financial statements.
Consolidated statement of cash flows
Unaudited Unaudited Audited
6 months to 6 months to 12 months to
30 June 30 June
2018 2017 31 December 2017
GBP GBP GBP
---------------------------------------------------------- ------------- ------------- -----------------
Cash flows from operating activities
Loss before taxation (1,513,997) (1,151,713) (2,449,767)
Adjustments for:
Depreciation and amortisation 161,592 79,980 209,228
Finance expenses 11,210 - 3,355
Finance income - (3) -
Share-based payments 19,428 19,173 109,523
---------------------------------------------------------- ------------- ------------- -----------------
Operating loss before working capital changes (1,321,767) (1,052,563) (2,127,661)
Changes in working capital
Increase in inventory (59,981) (129,726) (226,047)
Decrease in trade and other receivables 409,163 42,987 (463,134)
Decrease in trade and other payables (25,848) 199,410 280,937
---------------------------------------------------------- ------------- ------------- -----------------
Cash used in operations (998,433) (939,892) (2,535,905)
Tax received - 96,221 96,221
---------------------------------------------------------- ------------- ------------- -----------------
Net cash outflow from operating activities (998,433) (843,671) (2,439,684)
---------------------------------------------------------- ------------- ------------- -----------------
Investing activities
Purchase of property, plant and equipment (441,039) (512,686) (430,033)
Purchase of intangible assets (82,172) (117,149) (240,259)
Interest received on bank deposit account - 3 -
Net cash flows used in investing activities (523,211) (629,832) (670,292)
---------------------------------------------------------- ------------- ------------- -----------------
Financing activities
Issue of ordinary shares (net of issue expenses) - - 1,864,091
Interest paid on sale and leaseback (8,094) - (1,142)
Other interest paid (1,676)
Interest paid on loans and borrowings - - (784)
Proceeds from sale and leaseback 381,215 - 118,000
Repayment of sale and leaseback (139,388) - (40,907)
---------------------------------------------------------- ------------- ------------- -----------------
Net cash flows from financing activities 232,057 - 1,939,258
---------------------------------------------------------- ------------- ------------- -----------------
Net change in cash and cash equivalents (1,289,587) (1,473,503) (1,170,718)
Cash and cash equivalents at the beginning of the period 1,537,759 2,708,477 2,708,477
---------------------------------------------------------- ------------- ------------- -----------------
Cash and cash equivalents at the end of the period 248,172 1,234,974 1,537,759
---------------------------------------------------------- ------------- ------------- -----------------
Notes to the unaudited interim financial information for the 6 months ended 30 June 2018
1. General information
Concepta PLC (the "Company", formerly, Frontier Resources International PLC until 26 July 2016) is a public limited company incorporated and domiciled in England and Wales. The registered office of the Company is 1 Park
Row, Leeds, England, LS1 5AB. The registered company number is 06573154.
The principal activity of the Company and its subsidiary is in the development and commercialisation of mobile health diagnostics medical devices.
2. Significant accounting policies
Basis of preparation
The interim financial information for the six months ended 30 June 2018, which was approved by the Board of Directors on 26 September 2018, does not constitute statutory accounts as defined by section 434 of the Companies Act 2006.
The financial information have been prepared in accordance with International Financial Reporting Standards, International Accounting Standards and Interpretations (collectively IFRSs), as adopted by the European Union ("adopted IFRSs") and with those parts of the Companies Act 2006 applicable to companies reporting under IFRS.
The financial information presented is unaudited and has been prepared using the same accounting policies as those adopted in the financial statements for the year ended 31 December 2017 and expected to be adopted in the financial year ending 31 December 2018.
The interim financial information includes unaudited comparative figures for the unaudited 6 months to 30 June 2017 of Concepta Diagnostics Limited and comparatives for the year ended 31 December 2017 that have been extracted from the audited financial statements for that year.
The financial statements for the year ended 31 December 2017 were reported on by the Company's auditors and delivered to the Registrar of Companies. The report of the auditors was unqualified and did not contain an adverse statement under section 498 (2) or (3) of the Companies Act 2006.
In the opinion of the Directors, the interim financial information for the period presents fairly the financial position and the results from operations and cash flows for the period.
The following new IFRS standards became effective in the six months to the 30 June 2018 which had no material effect on this consolidated interim financial information.
1. IFRS 9 Financial instruments; and 2. IFRS 15 Revenue from contracts with customers.
Going concern
The Directors have prepared a cash flow forecast covering a period extending beyond 12 months from the date of this financial information.
The forecast contains certain assumptions about the performance of the business including growth in future revenue, the cost model and margins; and importantly the level of cash recovery from trading. The directors are aware of the risks and uncertainties facing the business but the assumptions used are the Directors' best estimate of the future development of the business.
After considering the forecasts and the risks, the Directors have a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future. For these reasons, they continue to adopt the going concern basis of accounting in preparing the annual financial statements. The financial information does not include any adjustments that would result from the going concern basis of preparation being inappropriate.
3. Segment information
The Group has one operating segment which is involved in the provision of diagnostic healthcare products. The operating segment has no revenue reported for the period to 30 June 2018.
4. Cost of sales
The cost of sales in the 6 months to June 2018 relates to costs incurred in the running of batches of products for product evaluation and trial testing, employees and contractors costs and running costs of the manufacturing site at Doncaster.
5. Loss per share
Unaudited Unaudited Audited
6 months to 6 months to 12 months to
30 June 2018 30 June 2017 31 December 2017
Basic and diluted
Loss for the period used in basic & diluted EPS (GBP) (1,490,349) (1,083,905) (2,344,949)
Weighted average number of shares used in basic and diluted EPS 138,196,675 109,625,247 112,564,863
Loss per share (pence) (1.1) (1.0) (2.1)
----------------------------------------------------------------- -------------- -------------- ------------------
Basic loss per share is calculated by dividing the loss attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the period.
Due to the loss in the periods the effect of the share options was considered anti-dilutive and hence no diluted loss per share information has been provided.
6. Taxation
Unaudited Unaudited Audited
6 months to 6 months to 12 months to
30 June 2018 30 June 2017 31 December 2017
GBP GBP GBP
------------------------------- -------------- -------------- ------------------
The tax credit is as follows:
UK Corporation tax
Tax credit - current period 23,648 67,808 104,818
Total current tax 23,648 67,808 104,818
------------------------------- -------------- -------------- ------------------
The tax credit represents the research and development tax credit for current interim and prior periods.
7. Property, plant and equipment
During the period the Group purchased new plant and equipment of GBP441,039 and this included certain equipment totaling GBP381,215 which was part of a sale and leaseback arrangement.
8. Intangible assets
The Group capitalised development costs of GBP82,172 during the interim period.
9. Related Party Transactions
Fees paid to other companies for directors' services and reimbursement of expenses for the period to 30 June 2018 were GBP94,670 (June 2017: GBP126,005; 31 December 2017: GBP218,676) and GBP8,296 (June 2017: GBP16,551; 31 December 2017:GBP10,400 ) were outstanding at period ended 30 June 2018.
This interim financial statement will be released in accordance with the AIM Rules for Companies, available shortly on the Company's website at www.conceptaplc.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
IR PGUPWBUPRGRQ
(END) Dow Jones Newswires
September 27, 2018 02:01 ET (06:01 GMT)
1 Year Concepta Chart |
1 Month Concepta Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
